A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Within months of its discovery, the INK4a (CDKN2A) and the genetically linked INK4b gene (CDKN2B) (36) were implicated in a reverse genetic screen to play tumor suppressive roles in familial melanoma (37).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [37]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
p53: At the Crossroads of Molecular Carcinogenesis and Risk Sssessment
Harris, C. C. (1993) · Science · doi:10.1126/science.8266092 · Cited by 475
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., & Arnold, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9638 · Cited by 432
Research works printed but not linked: 1
- Weaver-Feldhaus, J., Proceedings of the National Academy of Sciences of the United States of America 91: 7563 (1994).
Cited by
Items 101–200 of 1,005
DNA Copy Number Losses in Human Neoplasms
Knuutila, S., Aalto, Y., Autio, K., Björkqvist, A.-M., El-Rifai, W., Hemmer, S., Huhta, T., Kettunen, E., Kiuru-Kuhlefelt, S., Larramendy, M. L., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65166-8 · Cited by 397
THE CRITICAL ROLE OF CHROMOSOME TRANSLOCATIONS IN HUMAN LEUKEMIAS
Rowley, J. D. (1998) · Annual Review of Genetics · doi:10.1146/annurev.genet.32.1.495 · Cited by 397
Soufir, N. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.2.209 · Cited by 386
lavarone, A., & Massagué, J. (1997) · Nature · doi:10.1038/387417a0 · Cited by 377
Inhibition of Ras-Induced Proliferation and Cellular Transformation by p16 INK4
Serrano, M., Gómez-Lahoz, E., DePinho, R. A., Beach, D., & Bar-Sagi, D. (1995) · Science · doi:10.1126/science.7809631 · Cited by 373
Oncogene-Induced Cell Senescence — Halting on the Road to Cancer
Mooi, W. J., & Peeper, D. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062285 · Cited by 371
Absence of WAF1 mutations in a variety of human malignancies
Shiohara, M., el-Deiry, W., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D., Vogelstein, B., & Koeffler, H. (1994) · Blood · doi:10.1182/blood.v84.11.3781.bloodjournal84113781 · Cited by 368
BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines.
Wong, A. K., Shanahan, F., Chen, Y., Lian, L., Ha, P. C., Hendricks, K., Ghaffari, S. R., Iliev, D., Penn, B., Woodland, A.-M., et al. (2000) · PubMed · Cited by 429
Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site.
Schulze, A., Zerfass, K., Spitkovsky, D., Middendorp, S., Bergès, J., Helin, K., Jansen-Dürr, P., & Henglein, B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11264 · Cited by 361
Molecular Genetics of Acute Lymphoblastic Leukemia
Armstrong, S. A., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.047 · Cited by 362
Li, Y., Nichols, M. A., Shay, J. W., & Xiong, Y. (1994) · PubMed · Cited by 410
Khleif, S. N., DeGregori, J., Yee, C. L., Otterson, G. A., Kaye, F. J., Nevins, J. R., & Howley, P. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4350 · Cited by 358
Opposing Effects of Ras on p53
Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., & McCormick, F. (2000) · Cell · doi:10.1016/s0092-8674(00)00123-9 · Cited by 357
Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway
Pumiglia, K. M., & Decker, S. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.448 · Cited by 356
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss
Terzian, T., Suh, Y.-A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 357
“Lastly, p16 loss, a common event in human cancers (Kamb et al. 1994; Nobori et al. 1994), also stabilized mutant p53 in vivo and yielded a metastatic phenotype.”
BackgroundFrom genes to drugs: targeted strategies for melanoma
Flaherty, K. T., Hodi, F. S., & Fisher, D. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3218 · Cited by 354
Parry, D., Bates, S., Mann, D. J., & Peters, G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07026.x · Cited by 354
Zhang, Y., & Xiong, Y. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80351-2 · Cited by 348
“…of human cancers, both familial andand link the human tumor-associated mutations in sporadic, at a frequency estimated to be close to thatARF with a functional alteration. of p53 locus (Kamb et al., 1994; Nobori et al., 1994; and recently compiled by Foulkes et al., 1997; Ruas and Peters, 1998).”
BackgroundBorg, A., Sandberg, T., Nilsson, K., Johannsson, O., Klinker, M., Masback, A., Westerdahl, J., Olsson, H., & Ingvar, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1260 · Cited by 345
“ternative exon 1 of the CDKN2A gene and an alternative reading frame within exon 2 of CDKN2A (22,23), or the CDKN2B gene, which encodes the p15INK4b protein ( 4 ).”
BackgroundResultTailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J. J., Richards, W. G., Sugarbaker, D. J., & Rollins, B. J. (1995) · PubMed · Cited by 377
Identification of Human and Mouse p19, a Novel CDK4 and CDK6 Inhibitor with Homology to p16ink4
Chan, F. K. M., Zhang, J., Cheng, L., Shapiro, D. N., & Winoto, A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2682 · Cited by 339
Zhao, X., Weir, B. A., LaFramboise, T., Lin, M., Beroukhim, R., Garraway, L., Beheshti, J., Lee, J. C., Naoki, K., Richards, W. G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4603 · Cited by 337
“The delineation of cancer-specific homozygous deletions enabled the discovery of several different tumor suppressor genes, including RB1 (1), CDKN2A (2, 3), PTEN (4, 5), and SMAD4/DPC4 (6).”
BackgroundInfluentialClinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia
Faderl, S., Kantarjian, H. M., Talpaz, M., & Estrov, Z. (1998) · Blood · doi:10.1182/blood.v91.11.3995 · Cited by 335
Regulatory Mechanisms of Tumor Suppressor P16INK4Aand Their Relevance to Cancer
Li, J., Poi, M. J., & Tsai, M.-D. (2011) · Biochemistry · doi:10.1021/bi200642e · Cited by 334
The retinoblastoma gene family: cousins with overlapping interests
Mulligan, G. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01470-x · Cited by 336
DNA Methylation: An Alternative Pathway to Cancer
Wajed, S. A., Laird, P. W., & DeMeester, T. R. (2001) · Annals of Surgery · doi:10.1097/00000658-200107000-00003 · Cited by 327
Lukas, J., Bartkova, J., & Bartek, J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6917 · Cited by 327
“Downloaded from mcb.asm.org by on February 16, 2010 of individual components of this pathway (4, 17, 18, 23, 26 , 33, 50, 63, 66).”
MethodKim, D. H., Nelson, H. H., Wiencke, J. K., Zheng, S., Christiani, D. C., Wain, J. C., Mark, E. J., & Kelsey, K. T. (2001) · PubMed · Cited by 365
Cyclin-Binding Motifs Are Essential for the Function of p21 CIP1
Chen, J., Saha, P., Kornbluth, S., Dynlacht, B. D., & Dutta, A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4673 · Cited by 320
Cdk inhibitors: on the threshold of checkpoints and development
Elledge, S. J., & Harper, J. W. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90055-8 · Cited by 320
p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors.
Ponce-Castañeda, M. V., Lee, M.-H., Latres, E., Polyák, K., Lacombe, L., Montgomery, K., Mathew, S., Krauter, K., Sheinfeld, J., & Massagué, J. (1995) · PubMed · Cited by 354
P16 gene in uncultured tumours
Spruck, C. H., Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M.-F., Gonzales, F., Tsai, Y. C., & Jones, P. A. (1994) · Nature · doi:10.1038/370183a0 · Cited by 318
Photocarcinogenesis: UVA vs. UVB Radiation
de Gruijl, F. R. (2002) · Skin Pharmacology and Physiology · doi:10.1159/000064535 · Cited by 315
Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies.
Kawamata, N., Morosetti, R., Miller, C. W., Park, D., Spirin, K. S., Nakamaki, T., Takeuchi, S., Hatta, Y., Simpson, J. F., & Wilcyznski, S. (1995) · PubMed · Cited by 340
Cell Cycle Control of Embryonic Stem Cells
White, J., & Dalton, S. (2005) · Stem Cell Reviews · doi:10.1385/scr:1:2:131 · Cited by 310
(2003) · PubMed
MC1R Genotype Modifies Risk of Melanoma in Families Segregating CDKN2A Mutations
Box, N. F., Duffy, D. L., Chen, W., Stark, M., Martin, N. G., Sturm, R. A., & Hayward, N. K. (2001) · The American Journal of Human Genetics · doi:10.1086/323412 · Cited by 310
“…different genes have been shown to influence risk of melanoma: cyclin-dependent kinase inhibitor 2A (CDKN2A [MIM 600160]) (Hussussian et al. 1994; Kamb et al. 1994a), cyclindependent kinase 4 (CDK4 [MIM 123829]) (Zuo et al. 1996; Soufir et al. 1998), and the melanocortin-1 receptor (MC1R [MIM…”
BackgroundHomozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
Gruis, N. A., van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., & Frants, R. R. (1995) · Nature Genetics · doi:10.1038/ng0795-351 · Cited by 310
Leary, R. J., Lin, J. C., Cummins, J., Boca, S., Wood, L. D., Parsons, D. W., Jones, S., Sjöblom, T., Park, B.-H., Parsons, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808041105 · Cited by 306
The Emerging Genetic Architecture of Type 2 Diabetes
Doria, A., Patti, M.-E., & Kahn, C. R. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.006 · Cited by 305
“CDKN2A encodes two molecules, p16INK4a and p14 (ARF), while CDKN2B encodes p15INK4b (Kamb et al., 1994; Pomerantz et al., 1998).”
Genetic alterations in breast cancer
Bièche, I., & Lidereau, R. (1995) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870140402 · Cited by 303
The genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., Laine, E., Greulich, H., Tseng, H., Gates, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2615 · Cited by 297
Ren, Z.-P., Pontén, F., Nistér, M., & Pontén, I. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960621)69:3<174::aid-ijc4>3.0.co;2-x · Cited by 96
Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review
Montesano, R., Holestein, M., & Hainaui, P. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960621)69:3<225::aid-ijc13>3.0.co;2-6 · Cited by 297
Franklin, D. S., Godfrey, V. L., O'Brien, D. A., Deng, C., & Xiong, Y. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.6147-6158.2000 · Cited by 297
“Their similar biochemical activity in blocking CDK enzymes and maintaining the growth-suppressive activity of Rb predict a tumor suppression function for CDK inhibitor genes, yet only the p16INK4a gene has been directly linked to tumor growth by genetic alterations found in human cancers ( 17 , 25) and by the early de…”
BackgroundThe H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15Ink4b
He, J., Kallin, E. M., Tsukada, Y.-I., & Zhang, Y. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1499 · Cited by 295
The CDKN2A (p16) Gene and Human Cancer
Foulkes, W. D., Flanders, T. Y., Pollock, P. M., & Hayward, N. K. (1997) · Molecular Medicine · doi:10.1007/bf03401664 · Cited by 292
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.
Tomlinson, G. E., Chen, T. T., Stastny, V., Virmani, A. K., Spillman, M. A., Tonk, V. S., Blum, J. L., Schneider, N. R., Wistuba, I. I., Shay, J. W., et al. (1998) · PubMed · Cited by 345
Genomic imprinting of p57KIP2, a cyclin–dependent kinase inhibitor, in mouse
Hatada, I., & Mukai, T. (1995) · Nature Genetics · doi:10.1038/ng1095-204 · Cited by 287
The INK4a/ARF tumor suppressor: one gene—two products—two pathways
Chin, L., Pomerantz, J., & DePinho, R. A. (1998) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01236-5 · Cited by 288
Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16776 · Cited by 286
A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.
Suzuki, K., Fueyo-Margareto, J., Krasnykh, V. N., Reynolds, P. N., Curiel, D. T., & Alemany, R. (2001) · PubMed · Cited by 286
Cyclin dependent kinase regulation
Lees, E. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80060-3 · Cited by 285
Cell-cycle regulators and cancer
Kamb, A. (1995) · Trends in Genetics · doi:10.1016/s0168-9525(00)89027-7 · Cited by 284
Mutations associated with familial melanoma impair p16INK4 function
Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. (1995) · Nature Genetics · doi:10.1038/ng0595-114 · Cited by 280
Murray, A. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90059-0 · Cited by 282
Hebert, J., Cayuela, J., Berkeley, J., & Sigaux, F. (1994) · Blood · doi:10.1182/blood.v84.12.4038.bloodjournal84124038 · Cited by 281
Schulze‐Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D. O., Meijer, L., Vesely, J., & Kim, S. (1995) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340220408 · Cited by 279
Whelan, A. J., Bartsch, D., & Goodfellow, P. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331505 · Cited by 280
Whole genome DNA copy number changes identified by high density oligonucleotide arrays
Huang, J., Wei, W., Zhang, J., Liu, G., Bignell, G. R., Stratton, M. R., Futreal, P., Wooster, R., Jones, K. W., & Shapero, M. H. (2004) · Human Genomics · doi:10.1186/1479-7364-1-4-287 · Cited by 279
“cancer,(30,31) while the p16/INK4 tumour suppressor on chromosome 9p21 has been shown to be deleted in a variety of tumour types.(32,33) Figure 3a shows a comparison across four samples for a region of chromosome 8 from 50 to 140Mb.”
BackgroundA germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family
Randerson-Moor, J. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.1.55 · Cited by 281
Melanoma epidemiology, biology and prognosis
Ali, Z., Yousaf, N., & Larkin, J. (2013) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2013.07.012 · Cited by 278
“During the normal cell cycle, CDK4 complexes with cyclin D, resulting in phosphorylation of the retinoblastoma (Rb1) protein, in turn releasing E2F-1 and thus allowing it to induce S-phase gene synthesis; p16 therefore acts as a negative regulator of the cell cycle [47,50].”
BackgroundThe p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bártková, J., Lukáš, J., Guldberg, P., Alsner, J., Kirkin, A. F., Zeuthen, J., & Bártek, J. (1996) · PubMed · Cited by 303
Mitogen-actived protein kinase activation is an early event in melanoma progression.
Cohen, C., Zavala-Pompa, Á., Sequeira, J., Shoji, M., Sexton, D. G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N. C., & Arbiser, J. L. (2002) · PubMed · Cited by 275
Mohseny, A. B., Szuhai, K., Romeo, S., Buddingh, E. P., Briaire‐de Bruijn, I., de Jong, D., van Pel, M., Cleton‐Jansen, A., & Hogendoorn, P. C. (2009) · The Journal of Pathology · doi:10.1002/path.2603 · Cited by 269
Clifford, S. C., Prowse, A. H., Affara, N. A., Buys, C. H. C. M., & Maher, E. R. (1998) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199807)22:3<200::aid-gcc5>3.0.co;2-# · Cited by 270
Genetic and epigenetic changes in nasopharyngeal carcinoma
Lo, K.-W., & Huang, D. P. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044579x02000883 · Cited by 269
Suzuki, T., Kitao, S., Matsushime, H., & Yoshida, M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00505.x · Cited by 269
Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes
Uchida, T., Kinoshita, T., Nagai, H., Nakahara, Y., Saito, H., Hotta, T., & Murate, T. (1997) · Blood · doi:10.1182/blood.v90.4.1403 · Cited by 269
Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia.
Myöhänen, S., Baylin, S. B., & Herman, J. G. (1998) · PubMed · Cited by 302
Homozygous deletion map at 18q21.1 in pancreatic cancer.
Hahn, S. A., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Schutte, M. E. M., Rozenblum, E., Seymour, A. B., Weinstein, C. L., Yeo, C. J., Hruban, R. H., et al. (1996) · PubMed · Cited by 265
Oral Cancer: Risk Factors and Molecular Pathogenesis
Ram, H., Sarkar, J., Kumar, H., Konwar, R., Bhatt, M. L. B., & Mohammad, S. (2011) · Journal of Maxillofacial and Oral Surgery · doi:10.1007/s12663-011-0195-z · Cited by 261
“p16 (CDKN2) present in this deleted region, is a potent inhibitor of cyclin D1 [ 31 ].”
BackgroundAbrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Vredeveld, L. C. W., Possik, P. A., Smit, M. A., Meissl, K., Michaloglou, C., Horlings, H. M., Ajouaou, A., Kortman, P. C., Dankort, D., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.187252.112 · Cited by 262
“Other frequent genetic events include the loss of CDKN2A and ARF, amplification of CCND1 or CDK4 (Kamb et al. 1994; Nobori et al. 1994; Freeman et al. 2003; Curtin et al. 2005), and, as identified more recently, alterations in MMP8, GRM3, ERBB4, GRIN2A (Palavalli et al.”
BackgroundInfluentialThe INK4a/ARF locus and melanoma
Sharpless, N. E., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206461 · Cited by 261
“Germline point mutations of p16INK4a were noted to cosegregate with tumor susceptibility in kindreds with familial melanoma (Hussussian et al., 1994; Kamb et al., 1994b; Holland et al., 1995; Liu et al., 1995; Walker *Correspondence: L Chin, Department of Dermatology, Harvard Medical School, 44…”
BackgroundSutherland, R. L., & Musgrove, E. A. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023591.45568.77 · Cited by 258
“Consistent with this hypothesis, deletion of INK4 occurred commonly in breast cancer cell lines and in one cell line (MDA-MB-361) loss of an allele was accompanied by mutation in the retained allele (24, 25, 52, 53 ).”
MethodResultReed, J. A., Loganzo, F., Shea, C. R., Walker, G. J., Flores, J. F., Glendening, J. M., Bogdany, J. K., Shiel, M. J., Haluska, F. G., & Fountain, J. W. (1995) · PubMed · Cited by 260
Misra, R. N., Xiao, H.-Y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 252
nmb, a novel gene, is expressed in low‐metastatic human melanoma cell lines and xenografts
Weterman, M. A. J., Ajubi, N., van Dinter, I. M. R., Degen, W. G. J., van Muijen, G. N. P., Ruiter, D. J., & Bloemers, H. P. J. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600111 · Cited by 256
The Retinoblastoma Protein Pathway in Cell Cycle Control and Cancer
Bartek, J., Bartkova, J., & Lukas, J. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3776 · Cited by 254
Role of the retinoblastoma protein in the pathogenesis of human cancer.
Sellers, W. R., & Kaelin, W. G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3301 · Cited by 253
Direct Inhibition of the Yeast Cyclin-Dependent Kinase Cdc28-Cln by Far1
Peter, M., & Herskowitz, I. (1994) · Science · doi:10.1126/science.8066461 · Cited by 252
Hepatic polyploidy and liver growth control
Gupta, S. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0317 · Cited by 251
The Retinoblastoma Protein: A Master Regulator of Cell Cycle, Differentiation and Apoptosis
Herwig, S., & Strauss, M. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00581.x · Cited by 250
Rogan, E. M., Bryan, T. M., Hukku, B., Maclean, K., Chang, A. C.-M., Moy, E. L., Englezou, A., Warneford, S. G., Dalla-Pozza, L., & Reddel, R. R. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.4745 · Cited by 250
Chang, J., Tan, W., Ling, Z., Xi, R., Shao, M., Chen, M., Luo, Y., Zhao, Y., Liu, Y., Huang, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15290 · Cited by 248
Oncogenic capacity of the E2F1 gene.
Johnson, D. G., Cress, W. D., Jakoi, L., & Nevins, J. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12823 · Cited by 249
Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes.
Beijersbergen, R. L., Carlée, L., Kerkhoven, R. M., & Bernards, R. (1995) · Genes & Development · doi:10.1101/gad.9.11.1340 · Cited by 248
Li, J.-M., Nichols, M. A., Chandrasekharan, S., Xiong, Y., & Wang, X.-F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26750 · Cited by 246
Molecular Biology of Lung Cancer: Clinical Implications
Larsen, J. E., & Minna, J. D. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.003 · Cited by 245
Molecular pathways in the formation of gliomas
von Deimling, A., Louis, D. N., & Wiestler, O. D. (1995) · Glia · doi:10.1002/glia.440150312 · Cited by 245
“which was originally identified as an amplified sequence in a murine sarcoma, and CDK4 have received particular attention since they may represent tumorigenic pathways alternative top53 gene inactivation (Kamb et al., 1994; Nobori et al., 1994; Oliner et al., 1992).”
BackgroundLoss of PTEN promotes tumor development in malignant melanoma.
Stahl, J. M., Cheung, M., Sharma, A. K., Trivedi, N. R., Shanmugam, S., & Robertson, G. P. (2003) · PubMed · Cited by 310
Hsieh, C. ‐., Klump, B., Holzmann, K., Borchard, F., Gregor, M., & Porschen, R. (1998) · PubMed · Cited by 241
Hildesheim, J., Bulavin, D. V., Anver, M. R., Alvord, W. G., Hollander, M. C., Vardanian, L., & Fornace, A. J. (2002) · PubMed · Cited by 283
Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers.
Nagatake, M., Takagi, Y., Osada, H., Uchida, K., Mitsudomi, T., Saji, S., Shimokata, K., Takahashi, T., & Takahashi, T. (1996) · PubMed · Cited by 241
Mechanisms of action of flavopiridol
Sedlacek, H. H. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00124-4 · Cited by 239
Potential Role of WAF1/Cip1/p21 as a Mediator of TGF-β Cytoinhibitory Effect
Li, C.-Y., Suardet, L., & Little, J. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.4971 · Cited by 239
Structural basis of inhibition of CDK–cyclin complexes by INK4 inhibitors
Jeffrey, P. D., Tong, L., & Pavletich, N. P. (2000) · Genes & Development · doi:10.1101/gad.851100 · Cited by 239
“…(for review, see Hall and Peters 1996): An INK4 inhibitor, p16INK4a (p16), is a tumor suppressor that is altered in >50% of certain tumor types (Kamb et al. 1994; Nobori et al. 1994; Hall and Peters 1996); cyclinD is often amplified in breast and prostate cancer (Hall and Peters 1996);…”
BackgroundFormation of p27-CDK complexes during the human mitotic cell cycle.
Soos, T. J., Kiyokawa, H., Yan, J. S., Rubin, M. S., Giordano, A., DeBlasio, A., Bottega, S., Wong, B., Mendelsohn, J. M., & Koff, A. (1996) · PubMed · Cited by 274
Metadata
- Authors
- Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H.
- Affiliations
- Myriad Genetics (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cross Cancer Institute (CA)
- National Institutes of Health (US)
- University of Utah (US)
- Venue
- Science
- Published
- 1994-04-15
- Volume
- 264
- Issue
- 5157
- Pages
- 436-440
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1983348452
- Cited by
- 2,751
- References
- 26
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 18 · 2023: 12 · 2022: 22 · 2021: 31 · 2020: 24 · 2019: 23 · 2018: 34 · 2017: 45 · 2016: 20 · 2015: 32 · 2014: 31 · 2013: 44 · 2012: 54
- FWCI
- 115.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca048711-05)
- National Cancer Institute (CA 48711)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDKN2A, p16, tumor suppressor, chromosome 9p, homozygous deletion, melanoma cell lines, CDK4, cell cycle regulation, genetic mutations
- MeSH terms
- Base Sequence, Carrier Proteins, Cell Cycle, Chromosomes, Human, Pair 9, Cosmids, Exons, Humans, Introns, Melanoma, Molecular Sequence Data, Mutation, Neoplasms, Proto-Oncogene Proteins, Tumor Cells, Cultured, Genes, Tumor Suppressor, Gene Deletion, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.